Industrial - Distribution
Build Your Comparison
Side-by-side financial analysisStock Comparison
TRNS vs SPXC vs JPM vs ROP vs BAC
Revenue, margins, valuation, and 5-year total return — side by side.
Industrial - Machinery
Banks - Diversified
Industrial - Machinery
Banks - Diversified
TRNS vs SPXC vs JPM vs ROP vs BAC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Industrial - Distribution | Industrial - Machinery | Banks - Diversified | Industrial - Machinery | Banks - Diversified |
| Market Cap | $852M | $11.54B | $896.00B | $34.48B | $422.78B |
| Revenue (TTM) | $333M | $2.35B | $280.33B | $8.12B | $191.57B |
| Net Income (TTM) | $7M | $254M | $57.05B | $1.71B | $30.51B |
| Gross Margin | 32.6% | 37.7% | 60.0% | 69.4% | 56.1% |
| Operating Margin | 4.1% | 16.9% | 25.9% | 28.1% | 19.7% |
| Forward P/E | 51.9x | 28.7x | 14.4x | 15.3x | 12.6x |
| Total Debt | $129M | $498M | $942.38B | $9.30B | $365.90B |
| Cash & Equiv. | $5M | $364M | $343.34B | $297M | $231.84B |
TRNS vs SPXC vs JPM vs ROP vs BAC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Transcat, Inc. (TRNS) | 100 | 352.9 | +252.9% |
| SPX Technologies, I… (SPXC) | 100 | 559.1 | +459.1% |
| JPMorgan Chase & Co. (JPM) | 100 | 341.0 | +241.0% |
| Roper Technologies,… (ROP) | 100 | 86.3 | -13.7% |
| Bank of America Cor… (BAC) | 100 | 235.9 | +135.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TRNS vs SPXC vs JPM vs ROP vs BAC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TRNS is the clearest fit if your priority is growth.
- 19.2% revenue growth vs BAC's -0.5%
SPXC has the current edge in this matchup, primarily because of its strength in growth exposure and long-term compounding.
- Rev growth 14.2%, EPS growth 17.9%, 3Y rev CAGR 15.7%
- 14.3% 10Y total return vs TRNS's 7.7%
- +44.9% vs ROP's -40.8%
- 7.1% ROA vs BAC's 0.9%, ROIC 13.4% vs 3.5%
JPM is the #2 pick in this set and the best alternative if valuation efficiency and bank quality is your priority.
- PEG 0.81 vs ROP's 1.59
- NIM 2.2% vs BAC's 1.8%
- Lower P/E (14.4x vs 15.3x), PEG 0.81 vs 1.59
- 1.9% yield, 15-year raise streak, vs BAC's 2.3%, (2 stocks pay no dividend)
ROP ranks third and is worth considering specifically for sleep-well-at-night.
- Lower volatility, beta 0.32, Low D/E 46.8%, current ratio 0.52x
- 21.1% margin vs TRNS's 2.0%
- Beta 0.32 vs SPXC's 1.38
BAC is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 12 yrs, beta 0.86, yield 2.3%
- Beta 0.86, yield 2.3%, current ratio 0.42x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.2% revenue growth vs BAC's -0.5% | |
| Value | Lower P/E (14.4x vs 15.3x), PEG 0.81 vs 1.59 | |
| Quality / Margins | 21.1% margin vs TRNS's 2.0% | |
| Stability / Safety | Beta 0.32 vs SPXC's 1.38 | |
| Dividends | 1.9% yield, 15-year raise streak, vs BAC's 2.3%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +44.9% vs ROP's -40.8% | |
| Efficiency (ROA) | 7.1% ROA vs BAC's 0.9%, ROIC 13.4% vs 3.5% |
TRNS vs SPXC vs JPM vs ROP vs BAC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
TRNS vs SPXC vs JPM vs ROP vs BAC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SPXC leads in 2 of 6 categories
ROP leads 1 • BAC leads 1 • TRNS leads 0 • JPM leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ROP leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 842.9x TRNS's $333M. ROP is the more profitable business, keeping 21.1% of every revenue dollar as net income compared to TRNS's 2.0%. On growth, SPXC holds the edge at +17.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $333M | $2.3B | $280.3B | $8.1B | $191.6B |
| EBITDAEarnings before interest/tax | $40M | $492M | $81.4B | $3.2B | $40.0B |
| Net IncomeAfter-tax profit | $7M | $254M | $57.0B | $1.7B | $30.5B |
| Free Cash FlowCash after capex | $20M | $385M | $100.9B | $2.6B | $12.6B |
| Gross MarginGross profit ÷ Revenue | +32.6% | +37.7% | +60.0% | +69.4% | +56.1% |
| Operating MarginEBIT ÷ Revenue | +4.1% | +16.9% | +25.9% | +28.1% | +19.7% |
| Net MarginNet income ÷ Revenue | +2.0% | +10.8% | +20.4% | +21.1% | +15.9% |
| FCF MarginFCF ÷ Revenue | +5.9% | +16.4% | +36.0% | +31.4% | +6.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.8% | +17.4% | — | +11.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -56.3% | +8.2% | +16.0% | +59.1% | +18.3% |
Valuation Metrics
BAC leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 14.7x trailing earnings, BAC trades at a 91% valuation discount to TRNS's 160.1x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs ROP's 2.46x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $852M | $11.5B | $896.0B | $34.5B | $422.8B |
| Enterprise ValueMkt cap + debt − cash | $976M | $11.7B | $1.50T | $43.5B | $556.8B |
| Trailing P/EPrice ÷ TTM EPS | 160.11x | 45.46x | 16.00x | 23.59x | 14.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 51.85x | 28.68x | 14.40x | 15.29x | 12.56x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.39x | 0.90x | 2.46x | 0.95x |
| EV / EBITDAEnterprise value multiple | 24.76x | 23.18x | 18.36x | 13.99x | 13.92x |
| Price / SalesMarket cap ÷ Revenue | 2.57x | 5.10x | 3.20x | 4.36x | 2.21x |
| Price / BookPrice ÷ Book value/share | 2.83x | 4.99x | 2.47x | 1.82x | 1.39x |
| Price / FCFMarket cap ÷ FCF | 43.60x | 47.86x | 8.88x | 13.83x | 33.52x |
Profitability & Efficiency
SPXC leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $2 for TRNS. SPXC carries lower financial leverage with a 0.22x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), BAC scores 7/9 vs JPM's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.2% | +12.4% | +15.9% | +8.8% | +10.1% |
| ROA (TTM)Return on assets | +1.4% | +7.1% | +1.3% | +5.0% | +0.9% |
| ROICReturn on invested capital | +2.6% | +13.4% | +4.5% | +6.1% | +3.5% |
| ROCEReturn on capital employed | +3.3% | +14.0% | +8.9% | +7.7% | +4.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 5 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.43x | 0.22x | 2.60x | 0.47x | 1.21x |
| Net DebtTotal debt minus cash | $124M | $134M | $599.0B | $9.0B | $134.1B |
| Cash & Equiv.Liquid assets | $5M | $364M | $343.3B | $297M | $231.8B |
| Total DebtShort + long-term debt | $129M | $498M | $942.4B | $9.3B | $365.9B |
| Interest CoverageEBIT ÷ Interest expense | 2.81x | 10.50x | 0.74x | 6.50x | 0.48x |
Total Returns (Dividends Reinvested)
SPXC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SPXC five years ago would be worth $38,893 today (with dividends reinvested), compared to $7,526 for ROP. Over the past 12 months, SPXC leads with a +44.9% total return vs ROP's -40.8%. The 3-year compound annual growth rate (CAGR) favors SPXC at 39.9% vs ROP's -8.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +59.7% | +13.2% | -0.5% | -22.5% | +1.1% |
| 1-Year ReturnPast 12 months | +17.9% | +44.9% | +21.8% | -40.8% | +28.1% |
| 3-Year ReturnCumulative with dividends | -1.0% | +173.6% | +138.2% | -24.1% | +103.0% |
| 5-Year ReturnCumulative with dividends | +66.3% | +288.9% | +118.2% | -24.7% | +47.1% |
| 10-Year ReturnCumulative with dividends | +769.1% | +1434.7% | +465.8% | +112.0% | +368.2% |
| CAGR (3Y)Annualised 3-year return | -0.3% | +39.9% | +33.6% | -8.8% | +26.6% |
Risk & Volatility
Evenly matched — ROP and BAC each lead in 1 of 2 comparable metrics.
Risk & Volatility
ROP is the less volatile stock with a 0.32 beta — it tends to amplify market swings less than SPXC's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BAC currently trades 97.3% from its 52-week high vs ROP's 58.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.35x | 1.38x | 0.94x | 0.32x | 0.86x |
| 52-Week HighHighest price in past year | $94.76 | $246.68 | $337.25 | $575.77 | $57.55 |
| 52-Week LowLowest price in past year | $50.23 | $152.79 | $262.71 | $305.96 | $43.66 |
| % of 52W HighCurrent price vs 52-week peak | +96.3% | +93.3% | +95.1% | +58.2% | +97.3% |
| RSI (14)Momentum oscillator 0–100 | 62.7 | 61.8 | 59.1 | 48.5 | 68.3 |
| Avg Volume (50D)Average daily shares traded | 155K | 561K | 7.0M | 1.1M | 31.7M |
Analyst Outlook
Evenly matched — JPM and BAC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: TRNS as "Buy", SPXC as "Buy", JPM as "Buy", ROP as "Buy", BAC as "Buy". Consensus price targets imply 36.6% upside for ROP (target: $458) vs 5.9% for JPM (target: $340). For income investors, BAC offers the higher dividend yield at 2.26% vs ROP's 0.98%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $123.60 | $252.00 | $339.75 | $457.64 | $61.13 |
| # AnalystsCovering analysts | 10 | 12 | 61 | 23 | 54 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.9% | +1.0% | +2.3% |
| Dividend StreakConsecutive years of raises | 0 | 0 | 15 | 12 | 12 |
| Dividend / ShareAnnual DPS | — | — | $5.95 | $3.29 | $1.27 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | 0.0% | +3.9% | +1.5% | +5.1% |
SPXC leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ROP leads in 1 (Income & Cash Flow). 2 tied.
TRNS vs SPXC vs JPM vs ROP vs BAC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is TRNS or SPXC or JPM or ROP or BAC a better buy right now?
For growth investors, Transcat, Inc.
(TRNS) is the stronger pick with 19. 2% revenue growth year-over-year, versus -0. 5% for Bank of America Corporation (BAC). Bank of America Corporation (BAC) offers the better valuation at 14. 7x trailing P/E (12. 6x forward), making it the more compelling value choice. Analysts rate Transcat, Inc. (TRNS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TRNS or SPXC or JPM or ROP or BAC?
On trailing P/E, Bank of America Corporation (BAC) is the cheapest at 14.
7x versus Transcat, Inc. at 160. 1x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Roper Technologies, Inc. 's 1. 59x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — TRNS or SPXC or JPM or ROP or BAC?
Over the past 5 years, SPX Technologies, Inc.
(SPXC) delivered a total return of +288. 9%, compared to -24. 7% for Roper Technologies, Inc. (ROP). Over 10 years, the gap is even starker: SPXC returned +1435% versus ROP's +112. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TRNS or SPXC or JPM or ROP or BAC?
By beta (market sensitivity over 5 years), Roper Technologies, Inc.
(ROP) is the lower-risk stock at 0. 32β versus SPX Technologies, Inc. 's 1. 38β — meaning SPXC is approximately 332% more volatile than ROP relative to the S&P 500. On balance sheet safety, SPX Technologies, Inc. (SPXC) carries a lower debt/equity ratio of 22% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — TRNS or SPXC or JPM or ROP or BAC?
By revenue growth (latest reported year), Transcat, Inc.
(TRNS) is pulling ahead at 19. 2% versus -0. 5% for Bank of America Corporation (BAC). On earnings-per-share growth, the picture is similar: Bank of America Corporation grew EPS 18. 6% year-over-year, compared to -63. 7% for Transcat, Inc.. Over a 3-year CAGR, SPXC leads at 15. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TRNS or SPXC or JPM or ROP or BAC?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus 1. 6% for Transcat, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ROP leads at 28. 3% versus 4. 0% for TRNS. At the gross margin level — before operating expenses — ROP leads at 69. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TRNS or SPXC or JPM or ROP or BAC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Roper Technologies, Inc. 's 1. 59x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 6x forward P/E versus 51. 9x for Transcat, Inc. — 39. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ROP: 36. 6% to $457. 64.
08Which pays a better dividend — TRNS or SPXC or JPM or ROP or BAC?
In this comparison, BAC (2.
3% yield), JPM (1. 9% yield), ROP (1. 0% yield) pay a dividend. TRNS, SPXC do not pay a meaningful dividend and should not be held primarily for income.
09Is TRNS or SPXC or JPM or ROP or BAC better for a retirement portfolio?
For long-horizon retirement investors, Roper Technologies, Inc.
(ROP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 32), 1. 0% yield, +112. 0% 10Y return). Both have compounded well over 10 years (ROP: +112. 0%, TRNS: +769. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TRNS and SPXC and JPM and ROP and BAC?
These companies operate in different sectors (TRNS (Industrials) and SPXC (Industrials) and JPM (Financial Services) and ROP (Industrials) and BAC (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: TRNS is a small-cap high-growth stock; SPXC is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock; ROP is a mid-cap quality compounder stock; BAC is a large-cap deep-value stock. JPM, ROP, BAC pay a dividend while TRNS, SPXC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.